Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06180577 · ClinicalTrials.gov registry record
A Survey Study to Assess the Accessibility of the Nerivio Device At School
A clinical trial, sponsored by Theranica.
- Completed
- Registry status
- 332
- Enrollment target
NCT06180577: Completed study, sponsored by Theranica.
NCT06180577 is a clinical trial that has completed, run by Theranica. The registered enrollment target is 332 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06180577 has completed, sponsored by Theranica.
- COMPLETED
- Registry status
- 332 participants
- Enrollment target
Study Summary
This is a retrospective survey-study to assess the accessibility, preference, and frequency of adolescents using Nerivio by itself, in combination with pharmacological medications, or not at all, in the school setting. The study population is prescribed Nerivio users, under the age of 18 years old, who have used the Nerivio device at least once. The study will be conducted electronically, and will include eligibility questions, an electronic informed consent form signed by the parent/legal guardian (e-ICF), an assent form signed by the adolescent patient (e-Assent), and an e-survey relating to the management of headaches due to migraine attacks. Participants will be recruited from Nerivio's userbase and will be compensated for their participation.
Primary Outcome
Percent of adolescents who prefer treating headaches due to migraine when they are at school with Nerivio alone, relative to other options (combination, pharmaceutical, not treating while in school).
Interventions
- DEVICE Nerivio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 332 participants |
| Start Date | 2024-02-01 |
| Est. Completion | 2024-05-15 |
What the finished NCT06180577 record still lists
NCT06180577 is an observational study that tracks outcomes without assigning an intervention. The registered 332 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Nerivio is the first listed.
NCT06180577 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06180577 about?
NCT06180577 is a clinical study titled "A Survey Study to Assess the Accessibility of the Nerivio Device At School". This is a retrospective survey-study to assess the accessibility, preference, and frequency of adolescents using Nerivio by itself, in combination with pharmacological medications, or not at all, in the school setting. The study population is prescribed Nerivio users, under the age of 18 years old, ...
What is the current status of trial NCT06180577?
This trial is currently completed. The enrollment target is 332 participants. The study started on 2024-02-01. Estimated completion is 2024-05-15.
What interventions are being tested in trial NCT06180577?
The interventions under investigation include: Nerivio (DEVICE).
Who is sponsoring clinical trial NCT06180577?
This trial is sponsored by Theranica, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174121 · 332 participants · Phase 2
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- NCT02605785 · 332 participants · NA
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
- NCT04894006 · 332 participants · NA
Dementia Family Caregiver Study
- NCT05130606 · 332 participants · NA
CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI